<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>tradingpattern.net &#187; Healthcare</title>
	<atom:link href="http://www.tradingpattern.net/category/industry/biotech/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tradingpattern.net</link>
	<description>dedicated to value creation and applying the scientific method in finance</description>
	<lastBuildDate>Fri, 03 Feb 2012 20:30:56 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.2.1</generator>
		<item>
		<title>8&#215;8 (EGHT) Upgrade from Market Perform to Outperform &#8211; Analyst rating from Northland Securities</title>
		<link>http://www.tradingpattern.net/2011/08/09/8x8-eght-upgrade-from-market-perform-to-outperform-analyst-rating-from-northland-securities-2/</link>
		<comments>http://www.tradingpattern.net/2011/08/09/8x8-eght-upgrade-from-market-perform-to-outperform-analyst-rating-from-northland-securities-2/#comments</comments>
		<pubDate>Tue, 09 Aug 2011 16:19:30 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Upgrade]]></category>

		<guid isPermaLink="false">http://www.tradingpattern.net/?p=77639</guid>
		<description><![CDATA[]]></description>
		<wfw:commentRss>http://www.tradingpattern.net/2011/08/09/8x8-eght-upgrade-from-market-perform-to-outperform-analyst-rating-from-northland-securities-2/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>8&#215;8 ( EGHT ) Upgrade from Market Perform to Outperform &#8211; Analyst rating from Northland Securities</title>
		<link>http://www.tradingpattern.net/2011/08/09/8x8-eght-upgrade-from-market-perform-to-outperform-analyst-rating-from-northland-securities/</link>
		<comments>http://www.tradingpattern.net/2011/08/09/8x8-eght-upgrade-from-market-perform-to-outperform-analyst-rating-from-northland-securities/#comments</comments>
		<pubDate>Tue, 09 Aug 2011 14:23:30 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Upgrade]]></category>

		<guid isPermaLink="false">http://www.tradingpattern.net/?p=77561</guid>
		<description><![CDATA[]]></description>
		<wfw:commentRss>http://www.tradingpattern.net/2011/08/09/8x8-eght-upgrade-from-market-perform-to-outperform-analyst-rating-from-northland-securities/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>RDY &#8211;  Dr. Reddys Announces the Launch of Gemcitabine for Injection</title>
		<link>http://www.tradingpattern.net/2011/07/27/rdy-dr-reddys-announces-the-launch-of-gemcitabine-for-injection/</link>
		<comments>http://www.tradingpattern.net/2011/07/27/rdy-dr-reddys-announces-the-launch-of-gemcitabine-for-injection/#comments</comments>
		<pubDate>Wed, 27 Jul 2011 16:39:29 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Dr. Reddy's Laboratories]]></category>

		<guid isPermaLink="false">http://www.tradingpattern.net/?p=76337</guid>
		<description><![CDATA[]]></description>
		<wfw:commentRss>http://www.tradingpattern.net/2011/07/27/rdy-dr-reddys-announces-the-launch-of-gemcitabine-for-injection/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Dr. Reddy&#8217;s Q1 FY12 Financial Results</title>
		<link>http://www.tradingpattern.net/2011/07/20/dr-reddys-q1-fy12-financial-results/</link>
		<comments>http://www.tradingpattern.net/2011/07/20/dr-reddys-q1-fy12-financial-results/#comments</comments>
		<pubDate>Wed, 20 Jul 2011 16:14:43 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Dr. Reddy's Laboratories]]></category>

		<guid isPermaLink="false">http://www.tradingpattern.net/?p=75282</guid>
		<description><![CDATA[Key Highlights Consolidated revenues are at Rs. 19.7 billion ($444 million) in Q1 FY12 versus Rs. 16.8 billion ($377 million) in Q1 FY11, year-on-year growth of 18%. Revenues from Global Generics for Q1 FY12 are at Rs. 14.4 billion ($323 million). Year-on-year growth of 21% mainly driven by North America generics and Russia. Revenues from [...]]]></description>
		<wfw:commentRss>http://www.tradingpattern.net/2011/07/20/dr-reddys-q1-fy12-financial-results/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Dr. Reddy&#8217;s Laboratories</title>
		<link>http://www.tradingpattern.net/2011/06/01/dr-reddys-laboratories/</link>
		<comments>http://www.tradingpattern.net/2011/06/01/dr-reddys-laboratories/#comments</comments>
		<pubDate>Wed, 01 Jun 2011 21:18:43 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Dr. Reddy's Laboratories]]></category>

		<guid isPermaLink="false">http://www.tradingpattern.net/?p=70531</guid>
		<description><![CDATA[Dr. Reddy&#8217;s Laboratories is an integrated pharmaceutical company and operates in business segments such as global generics, active ingredients and proprietary products. Dr Reddy&#8217;s March quarter results were higher-than-estimated with revenue growing 22.8% year-over-year, driven by robust growth of 67.6% in U.S. generics and 25.7% in Russia and CIS. The launch of generic fexofenadine pseudoephedrine [...]]]></description>
		<wfw:commentRss>http://www.tradingpattern.net/2011/06/01/dr-reddys-laboratories/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Dr Reddy&#8217;s says U.S. court clears generic Allegra sale</title>
		<link>http://www.tradingpattern.net/2011/02/02/dr-reddys-says-u-s-court-clears-generic-allegra-sale/</link>
		<comments>http://www.tradingpattern.net/2011/02/02/dr-reddys-says-u-s-court-clears-generic-allegra-sale/#comments</comments>
		<pubDate>Wed, 02 Feb 2011 16:34:40 +0000</pubDate>
		<dc:creator>Martin</dc:creator>
				<category><![CDATA[Dr. Reddy's Laboratories]]></category>

		<guid isPermaLink="false">http://www.tradingpattern.net/?p=56059</guid>
		<description><![CDATA[&#8220;This is a positive for the company. Since Dr Reddy&#8217;s is the only player for this product, it should be able to do decent sales,&#8221; Sarabjit Kour Nangra, vice president of research and who tracks the sector at Angel Broking said. Dr. Reddy’s Laboratories announced today that on Friday, 28 January 2011, the U.S. District [...]]]></description>
		<wfw:commentRss>http://www.tradingpattern.net/2011/02/02/dr-reddys-says-u-s-court-clears-generic-allegra-sale/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Dr Reddy&#8217;s Laboratories will start to see the benefits from its tie-up with GlaxoSmithKline in two or three years</title>
		<link>http://www.tradingpattern.net/2011/02/02/dr-reddys-laboratories-will-start-to-see-the-benefits-from-its-tie-up-with-glaxosmithkline-in-two-or-three-years/</link>
		<comments>http://www.tradingpattern.net/2011/02/02/dr-reddys-laboratories-will-start-to-see-the-benefits-from-its-tie-up-with-glaxosmithkline-in-two-or-three-years/#comments</comments>
		<pubDate>Wed, 02 Feb 2011 16:33:09 +0000</pubDate>
		<dc:creator>Martin</dc:creator>
				<category><![CDATA[Dr. Reddy's Laboratories]]></category>

		<guid isPermaLink="false">http://www.tradingpattern.net/?p=56058</guid>
		<description><![CDATA[&#8220;Overall, it is a good relationship that is working well and going as predicted, but the financial impact is going to be seen only two to three years from now,&#8221; he told Reuters on the sidelines of the annual meeting of the World Economic Forum. &#8220;It takes time to develop the products and register them [...]]]></description>
		<wfw:commentRss>http://www.tradingpattern.net/2011/02/02/dr-reddys-laboratories-will-start-to-see-the-benefits-from-its-tie-up-with-glaxosmithkline-in-two-or-three-years/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>8&#215;8 (EGHT) Downgrade from Outperform to Market Perform &#8211; Analyst rating from Northland Securities</title>
		<link>http://www.tradingpattern.net/2011/01/27/8x8-eght-downgrade-from-outperform-to-market-perform-analyst-rating-from-northland-securities-2/</link>
		<comments>http://www.tradingpattern.net/2011/01/27/8x8-eght-downgrade-from-outperform-to-market-perform-analyst-rating-from-northland-securities-2/#comments</comments>
		<pubDate>Thu, 27 Jan 2011 17:54:53 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Downgrade]]></category>
		<category><![CDATA[Healthcare]]></category>

		<guid isPermaLink="false">http://www.tradingpattern.net/?p=55442</guid>
		<description><![CDATA[]]></description>
		<wfw:commentRss>http://www.tradingpattern.net/2011/01/27/8x8-eght-downgrade-from-outperform-to-market-perform-analyst-rating-from-northland-securities-2/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>8&#215;8 ( EGHT ) Downgrade from Outperform to Market Perform &#8211; Analyst rating from Northland Securities</title>
		<link>http://www.tradingpattern.net/2011/01/27/8x8-eght-downgrade-from-outperform-to-market-perform-analyst-rating-from-northland-securities/</link>
		<comments>http://www.tradingpattern.net/2011/01/27/8x8-eght-downgrade-from-outperform-to-market-perform-analyst-rating-from-northland-securities/#comments</comments>
		<pubDate>Thu, 27 Jan 2011 15:39:52 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Downgrade]]></category>
		<category><![CDATA[Healthcare]]></category>

		<guid isPermaLink="false">http://www.tradingpattern.net/?p=55356</guid>
		<description><![CDATA[]]></description>
		<wfw:commentRss>http://www.tradingpattern.net/2011/01/27/8x8-eght-downgrade-from-outperform-to-market-perform-analyst-rating-from-northland-securities/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Dr. Reddy’s Laboratories Ltd. (RDY) Q3 2011 Earnings Call</title>
		<link>http://www.tradingpattern.net/2011/01/26/dr-reddys-laboratories-ltd-rdy-q3-2011-earnings-call-january-25-2011-800-am-et/</link>
		<comments>http://www.tradingpattern.net/2011/01/26/dr-reddys-laboratories-ltd-rdy-q3-2011-earnings-call-january-25-2011-800-am-et/#comments</comments>
		<pubDate>Tue, 25 Jan 2011 23:28:23 +0000</pubDate>
		<dc:creator>Martin</dc:creator>
				<category><![CDATA[Dr. Reddy's Laboratories]]></category>

		<guid isPermaLink="false">http://www.tradingpattern.net/?p=55068</guid>
		<description><![CDATA[The financial highlights are as follows. Consolidated revenues for the quarter are at $424 million and represent a year-on-year growth of 10% and a sequential growth of 2%. Revenues from our Global Generics business stand at $303 million for the quarter, representing a year-on-year growth of 16%. Revenues from the Pharmaceutical Services and Active Ingredients [...]]]></description>
		<wfw:commentRss>http://www.tradingpattern.net/2011/01/26/dr-reddys-laboratories-ltd-rdy-q3-2011-earnings-call-january-25-2011-800-am-et/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

